234 related articles for article (PubMed ID: 26823828)
1. Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.
Yang J; Jiao S; Kang J; Li R; Zhang G
Int J Clin Exp Pathol; 2015; 8(11):14959-64. PubMed ID: 26823828
[TBL] [Abstract][Full Text] [Related]
2. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
[TBL] [Abstract][Full Text] [Related]
3. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
4. Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.
Myšíková D; Adkins I; Hradilová N; Palata O; Šimonek J; Pozniak J; Kolařík J; Skallová-Fialová A; Špíšek R; Lischke R
J Thorac Oncol; 2017 Feb; 12(2):249-257. PubMed ID: 27793776
[TBL] [Abstract][Full Text] [Related]
5. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ
J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346
[TBL] [Abstract][Full Text] [Related]
6. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.
Komatsu N; Jackson HM; Chan KF; Oveissi S; Cebon J; Itoh K; Chen W
Mol Immunol; 2013 Jul; 54(3-4):465-71. PubMed ID: 23454162
[TBL] [Abstract][Full Text] [Related]
7. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
Tang ZM; Ling ZG; Wang CM; Wu YB; Kong JL
PLoS One; 2017; 12(7):e0182117. PubMed ID: 28750095
[TBL] [Abstract][Full Text] [Related]
8. Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis.
Wang F; Lu J; Li S; Huo X; Liu X; Du X; Li C; Wang J; Chen Z
Anticancer Res; 2017 Aug; 37(8):4515-4522. PubMed ID: 28739747
[TBL] [Abstract][Full Text] [Related]
9. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1.
Türeci O; Mack U; Luxemburger U; Heinen H; Krummenauer F; Sester M; Sester U; Sybrecht GW; Sahin U
Cancer Lett; 2006 May; 236(1):64-71. PubMed ID: 15992994
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
11. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
[TBL] [Abstract][Full Text] [Related]
12. Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer.
Ma R; Xu H; Wu J; Sharma A; Bai S; Dun B; Jing C; Cao H; Wang Z; She JX; Feng J
Oncotarget; 2017 Mar; 8(12):18901-18913. PubMed ID: 28121629
[TBL] [Abstract][Full Text] [Related]
13. The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.
Wang Y; Wang Z; Ding Y; Sun F; Ding X
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2405-2407. PubMed ID: 31450913
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
[TBL] [Abstract][Full Text] [Related]
17. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
18. Urine antibody against human cancer antigen NY-ESO-1.
Jäger D; Stockert E; Karbach J; Herrlinger K; Atmaca A; Arand M; Chen YT; Gnjatic S; Old LJ; Knuth A; Jäger E
Cancer Immun; 2002 Aug; 2():10. PubMed ID: 12747755
[TBL] [Abstract][Full Text] [Related]
19. NY-ESO-1 antibody as a novel tumour marker of gastric cancer.
Fujiwara S; Wada H; Kawada J; Kawabata R; Takahashi T; Fujita J; Hirao T; Shibata K; Makari Y; Iijima S; Nishikawa H; Jungbluth AA; Nakamura Y; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Nakayama E; Mori M; Doki Y
Br J Cancer; 2013 Mar; 108(5):1119-25. PubMed ID: 23403818
[TBL] [Abstract][Full Text] [Related]
20. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
